High-risk Patients With Pancreatic Exocrine InsufficiencyEnteral Nutrition Feeding
Investigational drug(s) / intervention(s)
Short peptideProtein
Short peptide: Short peptide EN preparations were administered for nutritional support
Protein: Nutritional support therapy was administered with protein-type EN preparations
Study summary
The goal of this clinical trial is to systematically evaluate whether peptide-type enteral nutrition (EN) formulations improve protein uptake efficiency in high-risk groups at ICU PEI, using targeted amino acid metabolomics and gut microbiota co-metabolomics as core quantitative indicators.
Researchers will compare protein absorption efficiency of short-chain peptide and complete protein enteral nutrition formulas in high-risk populations for PEI in the ICU
Participants will:
Enteral nutrition was administered for ICU critically ill patients with high-risk factors for PEI
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age≥ 18 years old, no gender restriction;
* Meet the criteria for high-risk groups for PEI;
* AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria;
* Estimated duration of enteral nutrition support therapy: ≥7 days;
* The subject or their legally authorized family member must sign the informed consent form
Exclusion Criteria:
* Patients who have been clearly diagnosed with PEI or chronic persistent PEI;
* Patients who have contraindications to enteral nutrition therapy;
* Patients with severely impaired liver or kidney function;
* Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia;
* Patients who have received pancreatic enzyme replacement therapy or taken any medications that may affect protein absorption within 7 days prior to enrollment;
* Patients for whom the expected length of ICU stay is less than 7 days;
* Pregnant or lactating women, as well as patients with mental illnesses;
* Patients who are allergic to any component of the study medication.
Primary outcome measure(s)
Branched-chain amino acid concentration — Week 1
Citrulline concentration — Week 1
Urine 3-methylhistidine concentration — Week 1
Trial sites (1)
Facility
City
Region
Status
Shanghai Tongji Hospital
Shanghai
China
More Shanghai 10th People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.